Sign InSign Up

News & Views

|
News, Press Release, Views
|
Anova
Category: News, Press Release, Views

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas

Anova has announced enrollment of the first two patients in the highly anticipated study of DB107 for the treatment of brain tumors. The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed high-grade gliomas (HGG) when compared to historical performance.
|
Press Release
|
Anova
Category: Press Release

Anova Expands Leadership Team to Manage Growth and Drive Innovation

Anova proudly announces the appointment of Fred Ma, MD, PhD, Adam Callahan, MBA, and Rhonda Rosen, MBA, CPA., to key executive roles. The expansion of Anova’s leadership team reflects the companies significant growth, and adds decades of transformative leadership in the pharmaceutical, biotechnology, and medical device industries, to Anova’s leadership team. 
|
News, Press Release
|
Anova
Category: News, Press Release

Anova to Manage Study of DB107 Following Newly Awarded $11.8m CIRM Grant

Anova, a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed…
|
News, Press Release
|
Anova
Category: News, Press Release

Anova Supports the Design and Authorization of Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating the development of promising treatments to market announced the FDA authorization of a Phase II clinical trial to re-assess a targeted treatment in light of newly discovered pharmacogenomic predictor data in patients with newly diagnosed high-grade glioma (HGG)
|
News, Press Release
|
Anova
Category: News, Press Release

NeOnc Technologies Holdings Appoints Anova to Deliver its Phase 1/2 Trial of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care Therapy

NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received authorization by the U.S. Food and Drug Administration (FDA) for the Phase 1/2 clinical study of NEO212, the Company’s drug conjugate therapeutic under development. NEO212 is designed to more efficiently deliver a DNA alkylating agent to the brain for treatment of primary brain tumors and for brain metastases that…
|
News, Press Release
|
Anova
Category: News, Press Release

NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100

|| Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors. AnovaOS™ platform to support efficient patient identification and enrolment. Program designed to build upon early success of NEO100 with IDH1 mutated brain tumors (high-grade gliomas) in adult patients. NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology…
|
News, Press Release
|
Anova
Category: News, Press Release

Anova supports the design and delivery of a pilot AI/VR study

Anova is delighted to have supported the design and delivery of a pilot study aimed to examine whether the AI–VR Bubble app significantly reduced the intensity and/or frequency of hot flashes and improved psychological well-being and sleep in women with breast and/or ovarian cancer.
|
News, Press Release
|
Anova
Category: News, Press Release

Anova partners with Throne Biotechnologies for the development and management of early access program for Stem Cell Educator Therapy

Anova today announced a partnership with Throne Biotechnologies, Inc. (Throne Bio, ThroneBio.com) to provide early access to Stem Cell Educator (SCE) Therapy for patients with Type 1 Diabetes and other life-threatening autoimmune diseases. “Our partnership with Throne is a further demonstration of Anova’s commitment to increasing access to promising new treatments for patients in need,’ said Martin Walsh, President at…

Register today, connect your research network, 
and accelerate your research program.

Get started now
Up arrow
Our site uses cookies to improve your experience. By continuing to use this site, you agree to the use of cookies. You can find out more: Privacy Policy